Sort   by:  
 Page size 
UnknownPrediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
Not available
S-EPMC3221524 | biostudies-literature
UnknownBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Not available
S-EPMC4979199 | biostudies-literature
UnknownPhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Not available
S-EPMC4414320 | biostudies-literature
UnknownA phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Not available
S-EPMC4576993 | biostudies-literature
UnknownPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Not available
S-EPMC3804291 | biostudies-literature
UnknownPhase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Not available
S-EPMC3675699 | biostudies-literature
UnknownRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Not available
S-EPMC4878053 | biostudies-literature
UnknownDNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Not available
S-EPMC2815995 | biostudies-literature
UnknownPhase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
Not available
S-EPMC4205589 | biostudies-literature
UnknownValidation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Not available
S-EPMC3438234 | biostudies-literature
Sort   by:  
 Page size